Mario Raviglione, MD, is the World Health Organization’s Director of the Stop TB Department. He is a world leader in devising strategies to fight multi-drug resistant tuberculosis (MDR-TB). In an interview with John Donnelly on Friday, he responded to comments made by Ezekiel “Zeke” Emanuel, MD, PhD, Special Advisor for Health Policy at the Office of Management and Budget, in a blog post filed Thursday on Science Speaks. Here are excerpts from Raviglione’s interview.
Ezekiel “Zeke” Emanuel, MD, PhD, Special Advisor for Health Policy at the Office of Management and Budget, is currently on a two-week trip in Africa looking at various health programs. On Thursday, he visited St. Peter’s Specialized TB Hospital in Addis Ababa, Ethiopia, and afterward talked with John Donnelly about his impressions of the hospital, which treats 145 patients with multi-drug resistant tuberculosis (MDR-TB), and how the trip influenced his thinking about future strategies in fighting TB.
This is the first of two parts of the interview with Emanuel. On Friday, Science Speaks will run Emanuel’s impressions of an HIV prevention program along heavily traveled road corridor that pass along Djibouti, Ethiopia, Sudan and Kenya.
“These are not accidents or random events, but predictable consequences of complex interactions,” said Gerald Freidland, MD, as he painted a frightening picture of the emergence of extensively drug resistant (XDR) tuberculosis in Tugela Ferry, KwaZulu Natal, South Africa. He spoke to a packed audience at the 48th annual meeting of the Infectious Diseases Society […]
AIDS mortality in South Africa has seen an observed decrease at the population level from 2006-09 — the first time since the epidemic began, according to Jeffrey Klausner, MD, of the Centers for Disease Control and Prevention (CDC) in Pretoria. He presented on the impact of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) […]
Dr. Sten H. Vermund – a member of the Center’s Scientific Advisory Board – released a new report in Current HIV/AIDS Reports this week on the significance, challenges and opportunities in combination HIV prevention strategies. He suggests that these “prevention packages” be scaled up and their effectiveness evaluated.
A Lancet article this week examines the Stop TB Partnership. The piece outlines challenges to tuberculosis control and proposes solutions. It argues that treatment should be integrated into efforts to reduce poverty and treatment of other diseases that often co-exist with tuberculosis, and specific goals should be set to “inspire new partners to push for tuberculosis elimination.”
This week, the World Health Organization released its first report on neglected tropical diseases. Erin Hohlfelder at the ONE blog has a good post on the significance of this publication, saying it is the end of “report neglect” on NTDs.
The following post is by Center staff member David Bryden. An exciting and important step forward was taken this week by global partners working to stop TB. The Stop TB Partnership issued a revised and ambitious five-year plan to address TB in all its aspects. The plan overview is available on their website. South Africa […]
The U.S. Food and Drug Administration (FDA) announced $2.9 million to support six research projects related to the diagnosis, treatment and prevention of tuberculosis on Monday. This investment is a component of the FDA’s Critical Path Initiative (CPI)—a national strategy for transforming the way FDA-regulated products are developed, evaluated and manufactured. FDA launched the CPI […]